Status of preimplantation genetic testing and embryo selection

Reproductive Biomedicine Online
Santiago Munné

Abstract

At the recent 2018 PGDIS congress, a review of randomized controlled trials of preimplantation genetic testing for aneuploidies (PGT-A) showed improved ongoing pregnancy rates per transfer in experienced centres and in women aged 35 years and older. Young women produce 40% abnormal embryos (20-60% range), but not all centres see a selection advantage; this indicates the need for more emphasis in improving biopsy and case management. Some chromosome abnormalities are iatrogenic; PGT-A could, therefore, be used as assisted reproductive technology (ART) quality control. Great improvements in non-invasive PGT by testing spent media have been reported, ranging from 80-95% concordance with trophectoderm biopsy, probably precluding the need for biopsy soon. Mosaicism was widely discussed, with PGDIS agreeing to update their guidelines, but continuing to recommend prioritizing euploid, followed by mosaic embryos. Techniques to allow simultaneous single sample analysis of aneuploidy and inherited mutations are improving, but this does not extend to de-novo mutations. Convincing data were presented on the efficacy of using endometrial receptivity tests to improve ART outcomes adjuvant or independently of PGT-A. Imprinting, CRISPR and clo...Continue Reading

Citations

Feb 28, 2019·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Hayden Anthony Homer
Apr 18, 2019·Systems Biology in Reproductive Medicine·Michał KunickiKrzysztof Łukaszuk
Feb 28, 2020·Acta Obstetricia Et Gynecologica Scandinavica·Julius HreinssonHans Jakob Ingerslev
Aug 16, 2019·Journal of Translational Medicine·Federica CariatiRossella Tomaiuolo
Mar 4, 2020·Scientific Reports·Nicholas M MurphyLuk J F Rombauts
Oct 11, 2019·The CRISPR Journal·Manuel ViottiFrank L Barnes
Dec 16, 2019·Journal of Assisted Reproduction and Genetics·Xinyuan LiPing Zhou
Feb 14, 2021·Fertility and Sterility·Sonia M Suter
Feb 6, 2021·Obstetrics and Gynecology·Elias M Dahdouh
Feb 20, 2021·Reproductive Biology and Endocrinology : RB&E·Norbert GleicherUNKNOWN International Do No Harm Group in IVF (IDNHG-IVF)
Jun 11, 2021·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Hayden Anthony Homer
Jul 16, 2021·Reproductive Medicine and Biology·Hiroomi KawanoNaomi Kashiwazaki

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.